Kymera Therapeutics Inc. (KYMR)
KYMR trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1815442/000119312526073395/0001193125-26-073395-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | KYMR on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2020 |
| SEC CIK | 0001815442 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $39.2M |
| Net income | -$311.4M |
| Operating income | -$349.4M |
| Net margin | -794.0% |
| Operating margin | -891.1% |
| Revenue growth | -16.7% |
| Cash | $357.0M |
| Total assets | $1.7B |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 274.0× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-10-29 |
| Cash and burn | $373.4M cash; operating cash flow -$71.9M a quarter. | Report 2026-09-30 |
| Shares outstanding | 85,371,397 (2026-10-23); 71,949,027 a year earlier; 55,487,373 three years earlier. | Cover page 2026-10-23 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 3 424B5 takedowns, 3 at the market | Latest 2026-02-26 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, Boston, Massachusetts, United States | PCAOB Form AP 2026-03-10 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $172.5M, sold $475.4M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $0 | -$132.0M | -$77.9M | $373.4M | No debt tags | $102.2M | 10-Q 2026-10-29 |
| Q2 2026 2026-06-30 | $65.0M | -$61.2M | -$54.1M | $124.5M | No debt tags | $105.0M | 10-Q 2026-08-05 |
| Q1 2026 2026-03-31 | $34.4M | -$69.2M | -$88.8M | $144.1M | No debt tags | $51.5M | 10-Q 2026-04-30 |
| Q4 2025 2025-12-31 | $2.9M | -$87.0M | -$66.7M | $357.0M | No debt tags | $39.2M | 10-K 2026-02-26 |
| Q3 2025 2025-09-30 | $2.8M | -$82.2M | -$27.1M | $112.9M | No debt tags | $43.7M | 10-Q 2026-10-29 |
| Q2 2025 2025-06-30 | $11.5M | -$76.6M | -$59.9M | $335.8M | No debt tags | $44.7M | 10-Q 2026-08-05 |
| Q1 2025 2025-03-31 | $22.1M | -$65.6M | -$79.2M | $90.0M | No debt tags | $58.9M | 10-Q 2026-04-30 |
| Q4 2024 2024-12-31 | $7.4M | -$70.8M | -$61.8M | $120.3M | No debt tags | $47.1M | 10-K 2026-02-26 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2026-02-26 |
| Latest annual report | 10-K | 2026-02-26 |
| Latest quarterly / interim | 10-Q | 2026-10-29 |
| Latest current report | 8-K | 2026-10-29 |
| Latest proxy | DEFA14A | 2026-04-29 |
Source: SEC EDGAR submissions feed, 647 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -3.2% |
| 1 month | +19.6% |
| 3 months | +11.5% |
| Year to date | +64.0% |
| 1 year | +100.5% |
| From 52-week high | -8.1% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| HALO | Halozyme Therapeutics Inc. | $96.50 | -3.76% | $11.0B |
| RGEN | Repligen Corporation | $162.78 | -2.99% | $10.4B |
| QGEN | Qiagen N.V. Common Shares | $49.81 | -0.16% | $10.3B |
| TECH | Bio-Techne Corp | $72.79 | -0.01% | $11.4B |
| PCVX | Vaxcyte Inc. | $61.61 | -2.78% | $9.8B |
| KRYS | Krystal Biotech Inc. | $297.90 | -2.40% | $8.8B |
| CGON | CG Oncology Inc. | $84.78 | +13.95% | $7.6B |
| EXEL | Exelixis Inc. | $67.10 | -2.75% | $16.4B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier